Epilepsy drug dosage linked to specific birth defects

In a world first, new Australian medical research has given pregnant women with epilepsy new hope of reducing their chance of having a baby with physical birth defects.

According to research published in the September 2013 issue of Neurology, the medical journal of the American Academy of Neurology, epilepsy experts at The Royal Melbourne Hospital have discovered a link between high doses of common epilepsy drug valproate and the increased risk of having a baby with or hypospadias.

Royal Melbourne Hospital epilepsy specialist and Head of the Department of Medicine at The University of Melbourne, Professor Terry O'Brien, said there was increasing concern among clinicians, patients and their families about the risk to the developing fetus of mothers taking valproate.

"For many women on epilepsy medication, the desire to start a family can be fraught with fear that they could have a baby with a range of disabilities or malformations," Professor O'Brien said.

"Previous studies have shown a strong relationship between the dose of valproate taken and the risk of the child having a birth defect. However, for many women valproate is the only drug that will help control their seizures.

"Through our research, we now know that by reducing the dose taken in the first trimester of pregnancy, the risk of having a baby with spina bifida or will be greatly reduced."

Spina bifida is a birth defect of the spine and spinal cord, which occurs in utero in the first three months of pregnancy and cannot be cured. Hypospadias is a birth defect of the penis but can be treated with surgery.

Professor O'Brien added other birth defects such as and were still common irrespective of the drug dosage given to pregnant women.

The research data was extracted from the Australian Pregnancy Register (APR), based at The Royal Melbourne Hospital.

The APR has the data of more than 1700 women with epilepsy who have been or are currently pregnant, and is the world's most comprehensive pregnancy epilepsy database. Since its inception in 1999, the APR has gathered data that has been used to change epilepsy prescribing practices worldwide.

Founder of the APR and RMH Epilepsy specialist, Professor Frank Vajda AM, said the findings were statistically significant to make a real difference to the lives of women with epilepsy and their families.

"We always knew that drugs were responsible for the high level of fetal malformations but we never knew how much dosage played a role until recently," Professor Vajda said.

"The present findings for spina bifida are clinically significant, as 80 per cent of all instances of spina bifida in the APR were associated with valproate exposure.

"However, since the collection of data for the APR started, we have noted that valproate was being taken less often by pregnant women and in lower dosages.

"This evidence now tells us that by using in the lowest dose that can control severe seizures may reduce the hazard of one of the most devastating ."

add to favorites email to friend print save as pdf

Related Stories

Epilepsy drug may increase risk of birth defects

Jul 21, 2008

Taking the epilepsy drug topiramate alone or along with other epilepsy drugs during pregnancy may increase the risk of birth defects, according to a study published in the July 22, 2008, issue of Neurology, the medical journa ...

FDA warns pregnant women about migraine drugs

May 06, 2013

(HealthDay)—Pregnant women who struggle with migraine headaches should never use medicines containing the ingredient valproate because they can lower the IQ scores of their children, the U.S. Food and Drug ...

Epilepsy drug may increase risk of autism in children

Dec 01, 2008

A new study shows that women who take the epilepsy drug valproate while pregnant may significantly increase their child's risk of developing autism. The preliminary research is published in the December 2, 2008, print issue ...

Recommended for you

'Trigger' for stress processes discovered in the brain

5 hours ago

At the Center for Brain Research at the MedUni Vienna an important factor for stress has been identified in collaboration with the Karolinska Institutet in Stockholm (Sweden). This is the protein secretagogin ...

New research supporting stroke rehabilitation

Nov 26, 2014

Using world-leading research methods, the team of Dr David Wright and Prof Paul Holmes, working with Dr Jacqueline Williams from the Victoria University in Melbourne, studied activity in an area of the brain ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.